Khurram Jamil Sells 13,055 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 13,055 shares of Galectin Therapeutics stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $4.20, for a total value of $54,831.00. Following the completion of the sale, the insider directly owned 46,945 shares of the company’s stock, valued at $197,169. The trade was a 21.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Khurram Jamil also recently made the following trade(s):

• On Tuesday, January 6th, Khurram Jamil sold 21,446 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.65, for a total value of $78,277.90.
• On Monday, January 5th, Khurram Jamil sold 25,499 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.90, for a total value of $99,446.10.
• On Wednesday, December 17th, Khurram Jamil sold 19,442 shares of Galectin Therapeutics stock. The stock was sold at an average price of $7.04, for a total value of $136,871.68.
• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The shares were sold at an average price of $5.47, for a total value of $662,509.99.

Galectin Therapeutics Stock Up 2.6%

NASDAQ GALT opened at $3.54 on Thursday. The company has a 50-day moving average price of $5.27 and a 200-day moving average price of $4.39. Galectin Therapeutics Inc. has a 52 week low of $1.07 and a 52 week high of $7.13. The firm has a market capitalization of $228.23 million, a P/E ratio of -6.00 and a beta of 1.03.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, equities research analysts anticipate that Galectin Therapeutics Inc. will post -0.73 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. HC Wainwright boosted their price objective on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.00.

More Galectin Therapeutics News

Here are the key news stories impacting Galectin Therapeutics this week:

• Positive Sentiment: Analyst upgrade: HC Wainwright raised its price target and reiterated a “buy” on GALT in mid‑December, supporting upside sentiment and providing a bullish research anchor for the stock. MarketBeat – Analyst Note
• Neutral Sentiment: Institutional activity: small/new positions were reported from several funds (Nuveen, Atwood & Palmer, Hudson Bay, etc.) and Bank of America increased its stake; institutional ownership remains low (~11.7%) so impact is limited but worth monitoring. MarketBeat – Institutional Holdings
• Negative Sentiment: Regulatory / litigation risk: The Schall Law Firm and Pomerantz LLP announced investigations into Galectin that allege potential securities law violations; such probes typically increase legal risk and can pressure the stock until clarified. Schall Law Firm Investigation
• Negative Sentiment: Large, clustered insider selling: CEO Joel Lewis, CFO Jack Callicutt and insider Khurram Jamil sold sizable blocks across Jan. 2–6 (multiple Form 4s), trimming their ownership and raising concerns about insider sentiment or liquidity needs. Multiple filings may weigh on investor confidence. Form 4 – Joel Lewis
• Negative Sentiment: Insider sale summaries: CFO and other insiders sold tens of thousands of shares at prices between about $3.58–$4.20 in the same window; repeated insider sales amplify downside risk until rationale (e.g., diversification or personal liquidity) is disclosed. InsiderTrades – Sales Summary

Hedge Funds Weigh In On Galectin Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Atwood & Palmer Inc. bought a new position in shares of Galectin Therapeutics in the third quarter worth approximately $42,000. Archer Investment Corp bought a new stake in shares of Galectin Therapeutics during the 3rd quarter valued at $47,000. Hudson Bay Capital Management LP purchased a new position in shares of Galectin Therapeutics during the 3rd quarter valued at $63,000. JPMorgan Chase & Co. lifted its stake in shares of Galectin Therapeutics by 25.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,470 shares of the company’s stock valued at $66,000 after buying an additional 3,133 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in Galectin Therapeutics in the 3rd quarter worth $70,000. Hedge funds and other institutional investors own 11.68% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.